Senores Pharmaceuticals Share Price in Focus; Plans to Acquire Apnar Pharma Through Two-Stage Transaction

Senores Pharmaceuticals Limited has informed stock exchanges about its decision to acquire full ownership of Apnar Pharma Private Limited. 

The acquisition will be carried out through a share purchase agreement approved by the company’s management committee. 

The transaction is structured in two tranches and is expected to be completed over the current and next financial years.

Details of the Acquisition Agreement

The company has entered into a Share Purchase Agreement to acquire 100% of the equity share capital of Apnar Pharma Private Limited. 

Upon completion of both tranches, Apnar Pharma will become a wholly owned subsidiary of Senores Pharmaceuticals.

The transaction has been approved at the management level and disclosed under applicable listing regulations.

About Apnar Pharma Private Limited

Apnar Pharma is engaged in the manufacturing of generic pharmaceutical formulations. 

The company operates a manufacturing facility near Vadodara in Gujarat, which has approvals from the US Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency, and Health Canada.

Apnar Pharma was incorporated in December 2014 and has operations based in India.

Transaction Structure and Timeline

The acquisition is planned in two stages. The first tranche is expected to be completed within the current financial year by March 2026, while the second tranche is targeted for completion by the second quarter of FY 2027. 

No specific governmental or regulatory approvals have been indicated as necessary for completing the transaction.

Financial Consideration and Valuation

The total enterprise value of the acquisition is estimated at approximately ₹91 crore. This includes around ₹76 crore in debt and specified liabilities related to the manufacturing plant, which will be taken over by Senores Pharmaceuticals.

The remaining consideration of about ₹15 crore will be paid in cash, split between the two tranches, with a larger portion payable in the first phase.

Senores Pharmaceuticals Share Price Performance

Senores Pharmaceuticals’ shares were trading at ₹817 as of December 16, 2025, up 0.21% from the previous close of ₹815.25. During the session, the stock moved between an intraday high of ₹825.90 and a low of ₹810.15.

Read More: Senores Pharmaceuticals Share Price Rises 3%, Launches Deferiprone Tablets in US Market.

Conclusion

The proposed acquisition of Apnar Pharma marks a step in Senores Pharmaceuticals’ expansion within the pharmaceutical manufacturing space. 

The progress of the transaction will depend on timely completion of both tranches and subsequent operational integration over the coming quarters.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.